Who owns CLDX?
Institutional ownership of Celldex Therapeutics Inc. from Form 13F, Q2 2026
253 institutional managers reported holding Celldex Therapeutics Inc. (CLDX) in Form 13F filings for Q2 2026, with 85,805,194 shares worth $3.2B. The largest reported holder was Wellington Management Group LLP. Managers that filed both quarters added a net 12,961,457 shares (+17.8%). 45 opened new positions and 22 sold out.
- Funds holding
- 253
- Value held
- $3.2B
- New / sold out
- 45 / 22
- Net shares, same filers
- +17.8%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of CLDX
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Wellington Management Group LLP | $355M | 11.1% | 9,543,671 | Added |
| BlackRock, Inc. | $261M | 8.2% | 7,002,530 | Added |
| Kynam Capital Management, LP | $198M | 6.2% | 5,322,908 | Trimmed |
| Price T Rowe Associates Inc | $174M | 5.5% | 4,685,223 | Added |
| State Street Corp | $145M | 4.5% | 3,900,427 | Added |
| FMR LLC | $139M | 4.3% | 3,722,888 | Trimmed |
| Vanguard Capital Management LLC | $129M | 4.0% | 3,464,831 | Added |
| Deep Track Capital, LP | $109M | 3.4% | 2,939,151 | Added |
| Logos Global Management LP | $78.1M | 2.4% | 2,100,000 | Added |
| Geode Capital Management, LLC | $75.3M | 2.4% | 2,022,226 | Added |
| Eversept Partners, LP | $66.5M | 2.1% | 1,785,941 | Trimmed |
| Goldman Sachs Group Inc | $60.1M | 1.9% | 1,615,343 | Added |
| Assenagon Asset Management S.A. | $58.7M | 1.8% | 1,577,392 | Added |
| Commodore Capital LP | $50.2M | 1.6% | 1,350,000 | Trimmed |
| Bellevue Group AG | $44.7M | 1.4% | 1,200,000 | Unchanged |
| Baker Bros. Advisors LP | $44.0M | 1.4% | 1,182,611 | Added |
| Millennium Management LLC | $43.6M | 1.4% | 1,170,787 | Trimmed |
| Dimensional Fund Advisors LP | $40.0M | 1.3% | 1,073,985 | Added |
| American Century Companies Inc | $38.8M | 1.2% | 1,042,395 | Added |
| Eventide Asset Management, LLC | $38.6M | 1.2% | 1,037,000 | Unchanged |
| Novo Holdings A/S | $38.1M | 1.2% | 1,025,000 | Trimmed |
| Elmind Capital, LP | $36.8M | 1.2% | 990,000 | Added |
| Driehaus Capital Management LLC | $36.8M | 1.2% | 989,442 | New |
| Fisher Asset Management, LLC | $36.7M | 1.1% | 985,677 | Trimmed |
| Pictet Asset Management Holding SA | $34.1M | 1.1% | 917,408 | Trimmed |
Share of 13F holdings is each fund's shares as a share of the 85,805,194 CLDX shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Price T Rowe Associates Inc Added+$96.7M
- Deep Track Capital, LP Added+$61.6M
- Logos Global Management LP Added+$61.4M
- BlackRock, Inc. Added+$60.8M
- Assenagon Asset Management S.A. Added+$53.2M
- State Street Corp Added+$40.8M
- Driehaus Capital Management LLC New+$36.8M
- Wellington Management Group LLP Added+$36.6M
- Goldman Sachs Group Inc Added+$23.3M
- Foresite Capital Management VI LLC Added+$21.0M
Biggest sellers in Q2 2026
- Point72 Asset Management, L.P. Trimmed-$116M
- Commodore Capital LP Trimmed-$50.1M
- Vestal Point Capital, LP Sold out-$38.8M
- Braidwell LP Trimmed-$34.2M
- Kynam Capital Management, LP Trimmed-$19.3M
- Stempoint Capital LP Trimmed-$12.3M
- Novo Holdings A/S Trimmed-$6.5M
- Citadel Advisors LLC Sold out-$6.4M
- Silverarc Capital Management, LLC Sold out-$5.7M
- BNP Paribas Financial Markets Trimmed-$5.4M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $824M and sold $332M; 106 added and 57 trimmed.
Schedule 13D and 13G filings on CLDX
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-08-14PRICE T ROWE ASSOCIATES INC /MD/ SCHEDULE 13G filed by Celldex Therapeutics Inc.Schedule 13G
- 2026-05-12STATE STREET CORP SCHEDULE 13G filed by Celldex Therapeutics Inc.Schedule 13G
- 2026-02-09STATE STREET CORP SCHEDULE 13G filed by Celldex Therapeutics Inc.Schedule 13G
- 2025-02-14PRICE T ROWE ASSOCIATES INC /MD/ SCHEDULE 13G filed by Celldex Therapeutics Inc.Schedule 13G
Questions about CLDX ownership
- Who owns CLDX stock?
- 253 institutional investment managers reported CLDX positions in their Form 13F filings for Q2 2026, holding 85,805,194 shares worth $3.2B in total. Wellington Management Group LLP reported the largest position.
- Are funds buying or selling CLDX?
- In Q2 2026, 45 managers opened new CLDX positions, 106 added, 57 trimmed and 22 sold out. Managers that filed in both quarters added a net 12,961,457 shares.
- How current is this CLDX institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to CLDX by CUSIP. Options are left out. CLDX news and filings · CLDX insider trades · Top funds